<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31604369</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Peripheral immune biomarkers and neurodegenerative diseases: A prospective cohort study with 20&#x2009;years of follow-up.</ArticleTitle><Pagination><StartPage>913</StartPage><EndPage>926</EndPage><MedlinePgn>913-926</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.25614</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To assess the associations of several blood immune biomarkers with the future risks of amyotrophic lateral sclerosis and Parkinson disease in a prospective cohort study with 20&#x2009;years of follow-up.</AbstractText><AbstractText Label="METHODS">The Swedish Apolipoprotein-Related Mortality Risk study is a longitudinal cohort study including 812,073 participants with repeated blood biomarker measurements between 1985 and 1996 and a follow-up until 2011. Using a Cox model, we first estimated hazard ratios of amyotrophic lateral sclerosis and Parkinson disease in relation to leukocytes, immunoglobulin G, haptoglobin, and uric acid. We further described the temporal changes of these biomarkers during the 20&#x2009;years prior to the diagnosis of these diseases.</AbstractText><AbstractText Label="RESULTS">A total of 585 incident cases of amyotrophic lateral sclerosis and 3,769 incident cases of Parkinson disease were identified during the follow-up. Increasing concentrations of leukocytes, haptoglobin, and uric acid were associated with a lower risk of Parkinson disease. No statistically significant association was, however, noted between the studied biomarkers and amyotrophic lateral sclerosis. Parkinson disease patients appeared to have lower levels of leukocytes and haptoglobin between 20 and 10&#x2009;years before diagnosis and lower levels of uric acid during the 20&#x2009;years before diagnosis, compared to controls, although statistically significant differences were only noted during parts of the respective time intervals after multivariable adjustment. No clear differences were noted between patients with amyotrophic lateral sclerosis and controls.</AbstractText><AbstractText Label="INTERPRETATION">If verified in studies of independent populations, our findings may suggest a different role of systemic inflammation on the risk of Parkinson disease compared to amyotrophic lateral sclerosis. ANN NEUROL 2019;86:913-926.</AbstractText><CopyrightInformation>&#xa9; 2019 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yazdani</LastName><ForeName>Solmaz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariosa</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammar</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unit of Immunology and Allergy, Department of Medicine, Karolinska University Hospital, Solna.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Stockholm.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walldius</LastName><ForeName>G&#xf6;ran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3310-6456</Identifier><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>802091</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Potential Conflicts of Interest</b>
. Nothing to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31604369</ArticleId><ArticleId IdType="mid">EMS132544</ArticleId><ArticleId IdType="pmc">PMC7611591</ArticleId><ArticleId IdType="doi">10.1002/ana.25614</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease--a double-edged sword. Neuron. 2002;35:419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Godbout JP, Chen J, Abraham J, et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J. 2015;19:1329&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pubmed">15919760</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007;55:453&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871685</ArticleId><ArticleId IdType="pubmed">17203472</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauer W, Przedborski S. Parkinson&#x2019;s disease: mechanisms and models. Neuron. 2003;39:889&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">12971891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085.</Citation><ArticleIdList><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Molteni M, Rossetti C. Neurodegenerative diseases: The immunological perspective. J Neuroimmunol. 2017;313:109&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">29153601</ArticleId></ArticleIdList></Reference><Reference><Citation>Walldius G, Malmstrom H, Jungner I, et al. Cohort Profile: The AMORIS cohort. Int J Epidemiol. 2017;46:1103-1103i.</Citation><ArticleIdList><ArticleId IdType="pubmed">28158674</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisskopf MG, O&#x2019;Reilly E, Chen H, et al. Plasma urate and risk of Parkinson&#x2019;s disease. Am J Epidemiol. 2007;166:561&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2391073</ArticleId><ArticleId IdType="pubmed">17584757</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Mosley TH, Alonso A, et al. Plasma urate and Parkinson&#x2019;s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009;169:1064&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727240</ArticleId><ArticleId IdType="pubmed">19299404</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Zhang M, Quiroz Zarate A, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012;259:1923&#x2013;1928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441749</ArticleId><ArticleId IdType="pubmed">22323210</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly EJ, Liu D, Johns DR, et al. Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:120&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5531275</ArticleId><ArticleId IdType="pubmed">27677562</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Regodon Wallin A, Samuelsson K, et al. The Swedish motor neuron disease quality registry. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:528&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">30296856</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman AL, Johansson AL, Gatz M, et al. Accuracy and sensitivity of Parkinsonian disorder diagnoses in two Swedish national health registers. Neuroepidemiology. 2012;38:186&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375128</ArticleId><ArticleId IdType="pubmed">22472568</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscatell KA, Brosso SN, Humphreys KL. Socioeconomic status and inflammation: a meta-analysis. Molecular Psychiatry. 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6814496</ArticleId><ArticleId IdType="pubmed">31628416</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Johansson AL, Pedersen NL, et al. Socioeconomic status in relation to Parkinson&#x2019;s disease risk and mortality: A population-based prospective study. Medicine (Baltimore) 2016;95:e4337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5265853</ArticleId><ArticleId IdType="pubmed">27472716</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts AL, Johnson NJ, Chen JT, et al. Race/ethnicity, socioeconomic status, and ALS mortality in the United States. Neurology. 2016;87:2300&#x2013;2308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5135021</ArticleId><ArticleId IdType="pubmed">27742817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A, Schwarzschild MA. The epidemiology of Parkinson&#x2019;s disease: risk factors and prevention. Lancet Neurol. 2016;15:1257&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">27751556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85:470&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y, Fang F. Smoking and amyotrophic lateral sclerosis: A mendelian randomization study. Ann Neurol. 2019;85:482&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">30786056</ArticleId></ArticleIdList></Reference><Reference><Citation>King CC, Piper ME, Gepner AD, et al. Longitudinal Impact of Smoking and Smoking Cessation on Inflammatory Markers of Cardiovascular Disease Risk. Arterioscler Thromb Vasc Biol. 2017;37:374&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269476</ArticleId><ArticleId IdType="pubmed">27932354</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, et al. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Abbott RD, Petrovitch H, et al. Low LDL cholesterol and increased risk of Parkinson&#x2019;s disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008;23:1013&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">18381649</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Alonso A, Guo X, et al. Statins, plasma cholesterol, and risk of Parkinson&#x2019;s disease: a prospective study. Mov Disord. 2015;30:552&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390443</ArticleId><ArticleId IdType="pubmed">25639598</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson&#x2019;s disease. Mov Disord. 2007;22:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1906875</ArticleId><ArticleId IdType="pubmed">17177184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima WG, Martins-Santos ME, Chaves VE. Uric acid as a modulator of glucose and lipid metabolism. Biochimie. 2015;116:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">26133655</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. The Role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011;11:246&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in Parkinson&#x2019;s disease. J Parkinsons Dis. 2013;3:493&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102262</ArticleId><ArticleId IdType="pubmed">24275605</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Hammar N, Malmstrom H, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol. 2017;81:718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozani V, Gurevich T, Giladi N, et al. Higher serum cholesterol and decreased Parkinson&#x2019;s disease risk: A statin-free cohort study. Mov Disord. 2018;33:1298&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pubmed">30145829</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Bender DE, Kashlan SR, et al. Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897983</ArticleId><ArticleId IdType="pubmed">27308304</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, et al. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol. 2017;74:1446&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L, Muller K, Khalaji S, et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 2016;132:391&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, Staff NP, Bornschlegl S, et al. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS One. 2017;12:e0182002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Lindberg RL, Regeniter A, et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol. 2009;16:771&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Devos D, Brunaud-Danel V, et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology. 2005;65:1958&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson&#x2019;s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603346</ArticleId><ArticleId IdType="pubmed">26464797</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch EC, Hunot S. Neuroinflammation in Parkinson&#x2019;s disease: a target for neuroprotection? Lancet Neurol. 2009;8:382&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">19296921</ArticleId></ArticleIdList></Reference><Reference><Citation>Rektor I, Goldemund D, Sheardova K, et al. Vascular pathology in patients with idiopathic Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2009;15:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">18403246</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119:182&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613467</ArticleId><ArticleId IdType="pubmed">19104149</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens CH, Rowe D, Morel-Kopp MC, et al. Reduced T helper and B lymphocytes in Parkinson&#x2019;s disease. J Neuroimmunol. 2012;252:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22910543</ArticleId></ArticleIdList></Reference><Reference><Citation>Blandini F, Mangiagalli A, Cosentino M, et al. Peripheral markers of apoptosis in Parkinson&#x2019;s disease: the effect of dopaminergic drugs. Ann N Y Acad Sci. 2003;1010:675&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033810</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliore L, Petrozzi L, Lucetti C, et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson&#x2019;s disease patients. Neurology. 2002;58:1809&#x2013;1815.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084881</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, O&#x2019;Reilly EJ, Schwarzschild MA, et al. Peripheral inflammatory biomarkers and risk of Parkinson&#x2019;s disease. Am J Epidemiol. 2008;167:90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890755</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>Frutiger K, Lukas TJ, Gorrie G, et al. Gender difference in levels of Cu/Zn superoxide dismutase (SOD1) in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9:184&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">18574763</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumenko N, Pollari E, Kurronen A, et al. Gender-Specific Mechanism of Synaptic Impairment and Its Prevention by GCSF in a Mouse Model of ALS. Front Cell Neurosci. 2011;5:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3238042</ArticleId><ArticleId IdType="pubmed">22180738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kustrimovic N, Comi C, Magistrelli L, et al. Parkinson&#x2019;s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naive and drug-treated patients. J Neuroinflammation. 2018;15:205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6044047</ArticleId><ArticleId IdType="pubmed">30001736</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>